GTHP
GUIDED THERAPEUTICS INCCompany Intelligence Hub
Filing history, signal momentum, and bull/bear evolution
Chronological Filing Evolution (Click to filter / toggle)
Thesis (Bull Case Evolution)
Guided Therapeutics is approaching a critical inflection point as it prepares to transition from a clinical-stage entity to a commercial healthcare provider.…
Antithesis (Bear Case / Structural Risks)
The financial reality disclosed in the 10-K reveals a company teetering on the edge of insolvency. With a cash balance of only $63K and total liabilities of $7.3M, Guided Therapeutics is operating under a 'substantial doubt' going-concern opinion from its auditors.…
Read the full bull/bear analysis
You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every GTHP filing.
Synthesis (Verdict & Resolution)
The Guided Therapeutics filing presents a stark contrast between a high-potential medical technology and a distressed financial entity. On one hand, the clinical success of the LuViva device and the proximity to FDA and NMPA approvals offer a legitimate path to massive scale. On the other hand, the company's immediate survival is not guaranteed, as evidenced by the severe liquidity shortage and the default on its primary debt instruments. The investment case rests entirely on whether the company can secure enough bridge financing to reach its 2026 regulatory milestones. Ultimately, the 10-K highlights a binary outcome. If the FDA application in Q2 2026 is successful, the company may find the capital necessary to clear its debt and scale operations. However, any further regulatory delays or failure to secure immediate funding will likely lead to bankruptcy or extreme dilution. Investors are essentially betting on a clinical breakthrough to rescue a failing balance sheet.
Core Takeaway
The company is racing toward FDA/NMPA approvals in 2026 while battling a severe liquidity crisis and defaulted debt.
Investor Lens
The trade-off is between the high-conviction clinical data and the extreme risk of total capital loss or 68% dilution.
Watch Next
The submission of the FDA PMA application in Q2 2026 and any new capital raise announcements.
Signal Momentum Chart
Quarterly net bull/bear signal ratio. Click nodes to select a quarter.
Signal Timeline
Filing History
The Guided Therapeutics filing presents a stark contrast between a high-potential medical technology and a distressed financial entity. On one hand, the clinical success of the LuViva device and the proximity to FDA and NMPA approvals offer a legitimate path to massive scale. On the other hand, the company's immediate survival is not guaranteed, as evidenced by the severe liquidity shortage and the default on its primary debt instruments. The investment case rests entirely on whether the company can secure enough bridge financing to reach its 2026 regulatory milestones. Ultimately, the 10-K highlights a binary outcome. If the FDA application in Q2 2026 is successful, the company may find the capital necessary to clear its debt and scale operations. However, any further regulatory delays or failure to secure immediate funding will likely lead to bankruptcy or extreme dilution. Investors are essentially betting on a clinical breakthrough to rescue a failing balance sheet.
Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.